This company has been acquired
Resumen de acción FMTX
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Competidores de Forma Therapeutics Holdings, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.01 |
| 52 Week High | US$20.68 |
| 52 Week Low | US$4.95 |
| Beta | -0.95 |
| 1 Month Change | 0.25% |
| 3 Month Change | 138.50% |
| 1 Year Change | 10.61% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -48.69% |
Noticias y actualizaciones recientes
We're Keeping An Eye On Forma Therapeutics Holdings' (NASDAQ:FMTX) Cash Burn Rate
Aug 30
Forma Therapeutics GAAP EPS of -$1.10 misses by $0.11
Aug 05Recent updates
We're Keeping An Eye On Forma Therapeutics Holdings' (NASDAQ:FMTX) Cash Burn Rate
Aug 30Forma Therapeutics GAAP EPS of -$1.10 misses by $0.11
Aug 05We're Hopeful That Forma Therapeutics Holdings (NASDAQ:FMTX) Will Use Its Cash Wisely
Mar 04We're Hopeful That Forma Therapeutics Holdings (NASDAQ:FMTX) Will Use Its Cash Wisely
Nov 20Here's Why We're Not Too Worried About Forma Therapeutics Holdings' (NASDAQ:FMTX) Cash Burn Situation
Aug 13We Think Forma Therapeutics Holdings (NASDAQ:FMTX) Needs To Drive Business Growth Carefully
Apr 18What Type Of Shareholders Own The Most Number of Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) Shares?
Jan 03Forma Therapeutics closes public offering priced at $45.25
Dec 16Forma Therapeutics prices equity offering at $45.25
Dec 11Forma Therapeutics' sickle cell treatment shows promising action at ASH presentation
Dec 08Forma Therapeutics EPS beats by $0.01
Nov 12Forma Therapeutics' sickle cell candidate an orphan drug in Europe
Nov 10Rentabilidad de los accionistas
| FMTX | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 0.3% | 4.7% | 0.7% |
| 1Y | 10.6% | 2.7% | 23.9% |
Rentabilidad vs. Industria: FMTX exceeded the US Biotechs industry which returned -22.4% over the past year.
Rentabilidad vs. Mercado: FMTX exceeded the US Market which returned -25.7% over the past year.
Volatilidad de los precios
| FMTX volatility | |
|---|---|
| FMTX Average Weekly Movement | 15.9% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: FMTX's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: FMTX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2007 | 189 | Frank Lee | www.formatherapeutics.com |
Resumen de fundamentos de Forma Therapeutics Holdings, Inc.
| Estadísticas fundamentales de FMTX | |
|---|---|
| Capitalización bursátil | US$957.72m |
| Beneficios(TTM) | -US$190.15m |
| Ingresos (TTM) | n/a |
0.0x
Ratio precio-ventas (PS)-5.0x
Ratio precio-beneficio (PE)¿Está FMTX sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de FMTX | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$127.07m |
| Beneficio bruto | -US$127.06m |
| Otros gastos | US$63.09m |
| Beneficios | -US$190.15m |
Últimos beneficios comunicados
Jun 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -3.97 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado FMTX a largo plazo?
Ver rendimiento histórico y comparativa